NO951219L - Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav - Google Patents

Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav

Info

Publication number
NO951219L
NO951219L NO951219A NO951219A NO951219L NO 951219 L NO951219 L NO 951219L NO 951219 A NO951219 A NO 951219A NO 951219 A NO951219 A NO 951219A NO 951219 L NO951219 L NO 951219L
Authority
NO
Norway
Prior art keywords
plasminogen
blood clots
liposomes
preparation
treatment
Prior art date
Application number
NO951219A
Other languages
English (en)
Other versions
NO951219D0 (no
Inventor
Johanna Louise Maria Heeremans
Cornelius Kluft
Daniel Jan Anne Grommelin
Original Assignee
Stichting Tech Wetenschapp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Tech Wetenschapp filed Critical Stichting Tech Wetenschapp
Publication of NO951219D0 publication Critical patent/NO951219D0/no
Publication of NO951219L publication Critical patent/NO951219L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

Det omtales et farmasøytisk preparat for behandling av blodpropper såvel som et diagnostisk middel for på- visning av blodpropper. Preparatet omfatter et liposom eller en annen bionedbrytbar kolloidal bærer som har til seg bundet et plasminogen som et målsøkende stoff og om- fatter en plasminogenaktivator, og særlig en plasminogen- aktivator (tPA) av vevstypen, som blodproppoppløsende protein, eller et diagnostisk middel. Det omtales også en fremgangsmåte til fremstilling av et preparat med blodproppnedbrytende egenskaper, og fremgangsmåten innbefatter at plasminogen bindes til liposomer, idet plasminogenets affinitet overfor fibrin stort sett opprettholdes, og det inkorporeres en plas- minogenaktivator i liposomen under betingelser slik at samvirkningen mellom plasminogenet og plasminogenaktiva- toren nedsettes. Det omtales også en fremgangsmåte for å binde plas- minogen til liposomer idet et stort sett renset plasmino- gen anvendes som startmateriale.
NO951219A 1992-10-05 1995-03-30 Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav NO951219L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9201722A NL9201722A (nl) 1992-10-05 1992-10-05 Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan.
PCT/NL1993/000195 WO1994007537A1 (en) 1992-10-05 1993-10-05 Pharmaceutical composition for site-specific release of a clot-dissolving protein

Publications (2)

Publication Number Publication Date
NO951219D0 NO951219D0 (no) 1995-03-30
NO951219L true NO951219L (no) 1995-06-06

Family

ID=19861342

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951219A NO951219L (no) 1992-10-05 1995-03-30 Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav

Country Status (9)

Country Link
EP (1) EP0662841B1 (no)
JP (1) JPH08502060A (no)
AT (1) ATE171073T1 (no)
AU (1) AU5345494A (no)
CA (1) CA2146324A1 (no)
DE (1) DE69321131D1 (no)
NL (1) NL9201722A (no)
NO (1) NO951219L (no)
WO (1) WO1994007537A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
DE19529223A1 (de) * 1995-08-09 1997-02-13 Boehringer Mannheim Gmbh Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE831867A (fr) * 1975-07-29 1976-01-29 Association d'un activateur du plasminogene, d'une part, et du plasminogene lui-meme
JPS52102975A (en) * 1976-02-24 1977-08-29 Toyota Motor Corp Hydraulic driving system
US4193983A (en) * 1978-05-16 1980-03-18 Syva Company Labeled liposome particle compositions and immunoassays therewith
CA1297791C (en) * 1985-12-16 1992-03-24 Warren Douglas Sheffield Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time

Also Published As

Publication number Publication date
NL9201722A (nl) 1994-05-02
ATE171073T1 (de) 1998-10-15
DE69321131D1 (de) 1998-10-22
EP0662841B1 (en) 1998-09-16
EP0662841A1 (en) 1995-07-19
JPH08502060A (ja) 1996-03-05
CA2146324A1 (en) 1994-04-14
WO1994007537A1 (en) 1994-04-14
AU5345494A (en) 1994-04-26
NO951219D0 (no) 1995-03-30

Similar Documents

Publication Publication Date Title
JP5025868B2 (ja) 可逆的に不活性な酸性化プラスミン組成物の調製法
Björk et al. The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin.
Collen Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent
US5288490A (en) Thrombus-targeted complexes of plasminogen activator and fibrin fragments
DE69921102D1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
US7544500B2 (en) Process for the production of a reversibly inactive acidified plasmin composition
JP2631645B2 (ja) 新規化合物、その製法及びそれを含む医薬組成物
EP0333740B1 (en) Pharmaceutically active conjugates having improved body tissue binding specificity
HUT58812A (en) Process for producing tissue plasminogen activator (t-pa) zimogenes and compositions containing them as active components
US4902623A (en) Plasminogen activator
AU2036188A (en) New tissue plasminogen activator
ES2183805T3 (es) Procedimiento de preparacion de un medicamento trombolitico.
EP0355068A3 (en) Recombinant hybrid immunoglobulin molecules and their use
Bode et al. Thrombolysis by a fibrin-specific antibody Fab′-urokinase conjugate
Thorsen et al. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator
US5747291A (en) Bifunctional urokinase variants with improved fibrinolytic characteristics and thrombin inhibiting effect
Swenson et al. α-Fibrinogenases
NO951219L (no) Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav
EP0565512A1 (de) Verfahren zur Aktivierung von Blutgerinnungsfaktoren
RU2112528C1 (ru) СПОСОБ ПОЛУЧЕНИЯ ФЕРМЕНТА ДЕСТАБИЛАЗЫ, ОБЛАДАЮЩЕГО ФИБРИНОЛИТИЧЕСКОЙ, ТРОМБОЛИТИЧЕСКОЙ, ЭНДО- И ЭКЗО- ε(γ GLY)-LYS-ИЗОПЕПТИДАЗНОЙ И АМИДОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ
Bachmann Fibrinolytic agents
ES2033295T3 (es) Un metodo para preparar un activador de plasminogeno.
Suzuki et al. A study on the properties of commercial thrombin preparations
Dewerchin et al. Characterisation of conjugates of thrombin-treated single chain urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin
Yang et al. Construction and expression of a recombinant antibody targeted plasminogen activator